Preliminary Clinical Activity and Safety Profile SupportAdvancingto Dose ExpansioninMultiple Tumor Types Recommended Phase 2 Dose Determination OngoingPreclinicalCombinationDataforLeadDrug CandidateRepotrectinib inbothKRASTumor Modelsand Pediatric NeuroblastomaTumor ModelsAlsoPresentedConference Call Scheduled for11:00a.m.
"Oncogenic alterations in MET – including exon 14 deletion, amplifications, fusions and activating kinase domain mutations – occur in many tumor types and patients continue to have limited available therapies,"
Related News
Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer
PDF Version SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies...
Public Technologies 2020-10-21Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profilesfor RMC-4630...
Public Technologies 2020-10-24First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca
Milestonepayment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approachin R/M SCCHN patientswho have been treatedwith a...
Tyler Morning Telegraph
2020-10-23
SEC Filing (6-K) - Current Report by Foreign Issuer
EdgarFiling EXHIBIT 99.1 First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca Milestone payment further bolsters Innate's cash...
Public Technologies 2020-10-23Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory ...
TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2020-- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has...
The Marshall News Messenger
2020-10-22
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society's Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia
CAMBRIDGE, Mass., Oct. 23, 2020 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced the first patient has...
PR Newswire 2020-10-23Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting
October 24, 2020 Early Dose-Escalation Data Demonstrate Proof of Mechanism and Support Ongoing Development of SY-5609 for Difficult-to-Treat Cancers On Track to Report...
Public Technologies 2020-10-24